Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Scholar Rock advances myostatin programs, eyes regulatory milestones in 2024

Scholar Rock's Q3 performance reflects progress in myostatin programs and expansion into cardiometabolic disorders, supported by strong financials and partnerships.
The company's focus on myostatin biology, promising results of apitegromab and SRK-439, and engagement with regulatory authorities position them for future success.
While facing challenges in statistical assumptions, patient variability, and therapy safety, Scholar Rock's deep understanding of myostatin presents opportunities for growth and innovation.

Scholar Rock excels in Q3 with SMA breakthrough and strong financial backing

Scholar Rock's Q3 performance showcases promising advancements in SMA treatment and strategic initiatives to drive future growth and commercial success.
The company's strong financial position, diverse pipeline, and focus on patient-centric care position them well for potential market leadership.
While facing challenges in regulatory approval and market competition, Scholar Rock's proactive approach and innovative drug candidates present significant opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.

Scholar Rock Sees Hammer Chart Pattern: Time to Buy?

Is  (SRRK) Outperforming Other Medical Stocks This Year?

Is Scholar Rock Holding (SRRK) Stock Outpacing Its Medical Peers This Year?

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Tops Revenue Estimates

-  Completed enrollment of TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy

Scholar Rock Provides Corporate Update and Outlines Key R&D Priorities for 2020

CAMBRIDGE, Mass., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2019.

Scholar Rock Added to NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Nov.  19, 2019  (GLOBE NEWSWIRE) -- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of  SRK-015  for the treatment of patients with spinal muscular atrophy (SMA).  The planned preliminary PK/PD analysis, which includes data from 29 patients with SMA across all three cohorts, showed dose-proportional drug exposure and demonstrated target engagement, as evidenced by dose-dependent increases of up to 100-fold in the serum levels of latent myostatin following SRK-015 treatment (2 mg/kg and 20 mg/kg doses).  SRK-015 is a highly selective inhibitor of the precursor, or latent form, of myostatin, and was specifically designed to avoid interactions with related targets such as activins, GDF-11, or BMPs, to potentially improve the therapeutic profile compared to traditional non-selective inhibitors.

Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Misses Revenue Estimates

Fluidigm

Falling knives are stocks whose share price has fallen more than 59% over the past year, drawing interest from investors as these securities can deliver huge rewards if they rebound.

Analysts See 2 Falling Knives Bouncing Back

Preclinical and Phase 1 data support the evaluation of SRK-015 in ongoing Phase 2 trial for the treatment of patients with Type 2 and Type 3 spinal muscular trophy Preclinical and Phase 1 data support the evaluation of SRK-015 in ongoing Phase 2 trial for the treatment of patients with Type 2 and Type 3 spinal muscular trophy

Scholar Rock to Present Preclinical and Phase 1 Clinical Data on SRK-015 at the World Muscle Society Congress

As of late, it has definitely been a great time to be an investor Scholar Rock Holding.

Will Scholar Rock Continue to Surge Higher?

Highly experienced physician-scientist and drug developer to lead SRK-015 latent myostatin program Highly experienced physician-scientist and drug developer to lead SRK-015 latent myostatin program

Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise

CAMBRIDGE, Mass., Aug.  27, 2019  (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage biopharmaceutical company, announced today that its Chief Financial Officer, Rhonda Chicko, will be leaving the Company to pursue other opportunities. She will continue in the position through September 30, 2019 as she works with Scholar Rock’s senior management team to ensure a smooth transition. The Company has initiated a search for a new Chief Financial Officer.

News for Scholar Rock Holding Corp Stock (SRRK)